Literature DB >> 11747321

The surgical management of women with ovarian cancer in the south west of England.

A Olaitan1, J Weeks, A Mocroft, J Smith, K Howe, J Murdoch.   

Abstract

The surgical management of epithelial ovarian cancer in the South West of England was studied in the two years 1997-1998 in order to determine the factors that influence the outcome of surgery and to provide a baseline from which to assess the effect of centralisation of cancer services. All hospitals in the South West region of England participating in the Regional Cancer Organisation's longitudinal study of outcomes in gynaecological malignancies are included. Six hundred and eighty-two patients with epithelial ovarian cancer were registered with the RCO in the two-year study period. Five hundred and ninety-five women were offered primary cytoreductive surgery of which 438 were said to be optimally cytoreduced. Applying multivariate models to analyse the outcome of surgery, older patients (OR = 0.82 per 5-year increase in age, P = 0.0003), patients treated in hospitals managing fewer than ten cases of ovarian cancer per year (OR = 1.92, P = 0.02) and patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced. Gynaecological oncologists were 2.06 times more likely to attain optimal cytoreduction when compared to general gynaecologists and this was statistically significant (P = 0.01). The results from this study support the argument that limiting surgery for ovarian malignancy to specialised surgeons improves the extent of cytoreductive surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11747321      PMCID: PMC2364011          DOI: 10.1054/bjoc.2001.2196

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  The long learning curve of gynaecological cancer surgery: an argument for centralisation.

Authors:  J B Trimbos; B W Hellebrekers; G G Kenter; L A Peters; K H Zwinderman
Journal:  BJOG       Date:  2000-01       Impact factor: 6.531

2.  Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

Authors:  E J Junor; D J Hole; L McNulty; M Mason; J Young
Journal:  Br J Obstet Gynaecol       Date:  1999-11

3.  Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer.

Authors:  T Högberg; J Carstensen; E Simonsen
Journal:  Gynecol Oncol       Date:  1993-01       Impact factor: 5.482

4.  The management of cervical carcinoma within the south west region of England. Expert Tumour Panel.

Authors:  S Jackson; J Murdoch; K Howe; C Bedford; T Sanders; A Prentice
Journal:  Br J Obstet Gynaecol       Date:  1997-02

5.  National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system.

Authors:  H N Nguyen; H E Averette; W Hoskins; B U Sevin; M Penalver; A Steren
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

6.  Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

Authors:  R W Hunter; N D Alexander; W P Soutter
Journal:  Am J Obstet Gynecol       Date:  1992-02       Impact factor: 8.661

7.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

8.  Management of ovarian cancer: referral to a multidisciplinary team matters.

Authors:  E J Junor; D J Hole; C R Gillis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

9.  The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.

Authors:  S Kehoe; J Powell; S Wilson; C Woodman
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  9 in total
  7 in total

1.  Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Authors:  Yan Zhang; Chunxia Qiao; Lian Li; Xuye Zhao; Yali Li
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 2.  Centralisation of services for gynaecological cancer.

Authors:  Yin Ling Woo; Maria Kyrgiou; Andrew Bryant; Thomas Everett; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

3.  Management of complex pelvic masses using a multivariate index assay: a decision analysis.

Authors:  Kenneth H Kim; Gretchen N Zsebik; J Michael Straughn; Charles N Landen
Journal:  Gynecol Oncol       Date:  2012-05-30       Impact factor: 5.482

4.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

Review 5.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

6.  A case-control study to evaluate urinary tract complications in radical hysterectomy.

Authors:  Nadereh Behtash; Fatemeh Ghaemmaghami; Haleh Ayatollahi; Hediyeh Khaledi; Parviz Hanjani
Journal:  World J Surg Oncol       Date:  2005-02-16       Impact factor: 2.754

Review 7.  The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological Cancer.

Authors:  Lucas Minig; Pablo Padilla-Iserte; Cristina Zorrero
Journal:  Front Oncol       Date:  2016-01-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.